DROSPIRENONE WITH ETHINYLESTRADIOL

Brand name:

• Yaz®; Yasmin®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Oral contraceptive Moderate acne vulgaris in women who seek oral contraception Premenstrual dysphoric disorder in women who have chosen oral contraceptives as their method of birth control

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (Category 2)

Comment:

No further action, please see Yaz Yasmin link in Related medicines below.

Submission sponsor:

BAYER AUSTRALIA LTD

Other PBAC consideration:

• DROSPIRENONE WITH ETHINYLESTRADIOL

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 10/07/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

Awaiting lodgement from pharmaceutical company

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---